Which patients are assessed by lung cancer nurse specialists? A national lung cancer audit study of over 128,000 patients across england by Khakwani, A. et al.
This is an author produced version of Which patients are assessed by lung cancer nurse 
specialists? A national lung cancer audit study of over 128,000 patients across england.
White Rose Research Online URL for this paper:
http://eprints.whiterose.ac.uk/99227/
Article:
Khakwani, A., Hubbard, R.B., Beckett, P. et al. (5 more authors) (2016) Which patients are 
assessed by lung cancer nurse specialists? A national lung cancer audit study of over 
128,000 patients across england. Lung Cancer, 96. pp. 33-40. ISSN 0169-5002 
https://doi.org/10.1016/j.lungcan.2016.03.011
© 2016 Elsevier. This is an author produced version of a paper subsequently published in 
Lung Cancer. Uploaded in accordance with the publisher's self-archiving policy. Article 
available under the terms of the CC-BY-NC-ND licence 
(https://creativecommons.org/licenses/by-nc-nd/4.0/)
promoting access to
White Rose research papers
eprints@whiterose.ac.uk
http://eprints.whiterose.ac.uk/
1 
 
Which patients are assessed by Lung Cancer Nurse Specialists? A National 
Lung Cancer Audit study of over 128,000 patients across England 
Aamir Khakwani1, Richard B. Hubbard1, Paul Beckett2, Diana Borthwick3, Angela Tod4, 
Alison Leary5, John White6, Laila J. Tata1 
1. Division of Epidemiology and Public Health, University of Nottingham, Nottingham, 
NG5 1PB, UK 
2. Derby Hospital NHS Foundation Trust, Derby, DE22 3NE, UK 
3. Edinburgh Cancer Centre, Western General Hospital, EH4 2JT, UK 
4. School of Nursing, Midwifery and Social Work, Central Manchester NHS Foundation 
Trust, M13 9PL, UK 
5. School of Primary & Social Care, London South Bank University, SE1 0AA, UK  
6. St. James Hospital, Leeds Teaching Hospital, LS9 7TF, UK 
Funding: Dimbleby Cancer Care 
Key words: Lung Neoplasm, Non-small cell lung cancer, Small-cell lung cancer, Nurses, Health 
Services.  
Corresponding Author email: Aamir.Khakwani@nottingham.ac.uk 
Word Counts: 
Abstract = 249 
Manuscript = 2,984 
  
2 
 
Abstract 
Background: Lung cancer nurse specialists (LCNS) are integral to the multidisciplinary clinical 
team, providing personalised physical and psycho-social interventions, and care management for 
people with lung cancer. The National Institute of Health and Care Excellence (NICE) recommend 
that all patients have access to a LCNS. We conducted a national study assessing whether there is 
variation in access to and timing of LCNS assessment. 
Methods: 7KH1DWLRQDO&DQFHU$FWLRQ7HDP¶V/&16ZRUNIRUFHFHQVXVLQ(QJODQGZDVOLQNHGZLWK
patient and hospital Trust data from the English National Lung Cancer Audit. Multivariate logistic 
regression was used to assess features associated with LCNS assessment. 
Results: 128,124 lung cancer patients were seen from 2007-2011. LCNS assessment confirmation 
ZDVµ\HV¶LQµQR¶LQDQGµPLVVLQJ¶LQ:KHUHLQFOLQLFYHUVXVZDUGDQGZKHQEHIRUH
versus after diagnosis) patients were assessed by a LCNS also varied. Older patients with poor 
performance status, early cancer stage, and comorbidities were less likely to be assessed; there was no 
difference with sex or socioeconomic group. Patients receiving any anti-cancer treatment were more 
likely to be assessed. Assessment was lower in Trusts with high annual patient numbers (odds 
ratio=0.58, 95% confidence interval 0.37-0.91) and where LCNS caseload >250 (0.69, 0.41-1.16, 
although not statistically significant), but increased where workload was conducted mostly by band 8 
nurses (2.22, 1.22-4.02). 
Conclusion: LCNS assessment varied by patient and Trust features, which may indicate unmet need 
for some patients. The current workforce needs to expand as well as retain experienced LCNSs. 
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Introduction 
Lung cancer (LC) is the second most common cancer in the United Kingdom (UK) with 39,000 new 
cases annually in England [1 2]. Recent National Institute for Health and Care Excellence (NICE) 
guidelines recommend that every person diagnosed with LC has direct personal access to a Lung 
Cancer Nurse Specialist (LCNS) in their local hospital who they can meet with and be supported by 
throughout the cancer pathway [1 3]. LCNSs are now integral to the multidisciplinary team (MDT) 
within which they contribute to GHFLVLRQVRQWKHLUSDWLHQWV¶WUHDWPHQWDQGFDUH [4]. Previous research 
has shown the effectiveness of tailored nursing care and proactive LCNS case management in 
reducing unnecessary hospital admissions and doctor consultations, symptom control, emotional 
functioning and patient-reported satisfaction for early and metastatic LC [5-8]. A 2002 randomised 
control trial by Moore and colleagues of 203 patients showed that LCNS led follow-up was also cost-
effective when compared with conventional medical follow-up [8]. 
Although LC is the second commonest cancer in the UK [9], LCNSs comprise only 11% of the 
Cancer Nurse Specialists (CNSs) in England, compared with breast (20%), colorectal (14%) and 
urology (12%) CNSs [10]. A recent Macmillan report highlighted that on average, there is one LCNS 
for every 161 people diagnosed with LC, compared with 117 people diagnosed with breast cancer 
[11]. According to the 2013 National Lung Cancer Audit (NLCA) annual report, approximately 80% 
of all patients are now assessed by a LCNS, but there is variation by Trust and only 30% of LC 
patients are assessed in some Trusts [12].  
In this study we linked individual clinical information from the NLCA, the English Hospital Episode 
Statistics (HES) and Office of National Statistics (ONS) deaths with the National Cancer Action 
Team (NCAT) census on the LCNS workforce. We assessed whether, when and where patients are 
assessed by a LCNS and how clinical, demographic, socioeconomic status (SES) of patients and 
National Health Services (NHS) Trust characteristics including Trust size, LCNS salary bands and 
caseload affected their assessment. 
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Methods 
The NLCA collects key clinical information on all new patients presenting with a diagnosis of LC in 
the UK. In this study data from the NLCA was linked with HES, which includes all inpatient 
admissions in England, ONS mortality data to provide nationally registered dates of death, and 
NCAT, a census of the entire cancer specialist nurse workforce in England which provided details on 
the LCNS workforce. 
We included all patients in the NLCA who were first seen in England between January 1st, 2007 and 
December 31st, 2011 across 150 NHS Trusts in England. We used the latest NCAT census carried out 
in 2011 to map the workforce of 321 LCNS to NHS Trusts. Trusts without LCNS workforce 
information from the NCAT (n=4) were dropped leaving 146 Trusts for analysis. Patients diagnosed 
with LC through death certificate and those with mesothelioma or carcinoid were excluded. 
The NLCA records whether the patient is assessed by a LCNS (yes, no), date of assessment, timing of 
assessment in the cancer pathway and location of the first assessment. We categorised the timing of 
assessment as before/at diagnosis versus after diagnosis and the location of assessment as in clinic 
versus ward or other location (i.e. home visit, telephone or other). For each of the three variables, 
where no information was entered they were separately categorised as missing.  
Age at diagnosis, sex, SES, source of referral to a LC physician, performance status (classified 
according to WHO definition) and stage of disease (Union for International Cancer Control definition) 
were identified from NLCA. Data on active treatment were obtained from a combination of the 
NLCA and HES using methods as previously described [13-15] and categorised as no treatment, 
surgery, chemotherapy and radiotherapy, chemotherapy alone or radiotherapy alone. We used HES to 
calculate a SDWLHQW¶Vcomposite score of co-morbidity (Charlson Index). 
We used the NLCA to calculate the number of new LC patients seen annually in each Trust using our 
established methods [14]. We estimated HDFK 7UXVW¶V caseload per whole time equivalent (WTE) 
LCNS using the number of new cases first seen in 2011 plus the number of patients surviving since 
2004, divided by the number of WTE LCNSs employed at the Trust. We assumed that the patients 
5 
 
initially seen in a particular Trust were equally divided between the LCNSs employed by that Trust 
and that patients followed the LC pathway in that same Trust. Using NCAT information on salary 
bands of WTE LCNSs, we assessed the composition of the LCNS team at each trust. We also 
estimated which LCNS salary band conducted the majority of the work based on WTE employment at 
each Trust (e.g. Trust A was categorised at Band 7 if more than 50% of the total WTE LCNSs were 
on salary band 7). 
Statistical analysis 
All data analyses were performed using Stata MP12. Initially we plotted the percentage of patients 
recorded as having been assessed by a LCNS by the Trust size (average number of patients seen 
annually) and calculated the 3HDUVRQ¶V FRUUHODWLRQ coefficient to quantify the relationship. We used 
multinomial logistic regression analyses, to estimate the relative risk ratio (RRRs) of being assessed 
by a LCNS by patient and NHS Trust features. For all patients who had information on having been 
assessed, we also performed separate analyses to estimate the RRRs of being assessed after diagnosis 
versus before/at diagnosis and being assessed in clinic versus being assessed on wards. The 
unadjusted and adjusted RRR were clustered by NHS Trust to account for the hierarchical grouping of 
patient observations. A separate analysis was carried out for patients with missing data and a 
sensitivity analyses was conducted excluding all patients who died within 30 days of diagnosis to 
account for immortal time bias.  
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Results 
There were a total of 128,124 people with LC who were first seen between 1 January 2007 and 31 
December 2011, of whom 80,113 (63%) were seen by a LCNS, 7,544 (6%) were not seen and 40,467 
(31%) had missing data. The proportion of patients assessed increased over the study period (6,216 
(31%) in 2007 to 23,045 (80%) in 2011), mainly driven by a decrease in the missing data. From those 
who were assessed, 3,809 (5%) had missing information on the timing of first assessment and 8,317 
(10%) on the location. We observed a borderline moderate negative correlation between the number 
of new cases seen at a Trust and the proportion of patients assessed by a LCNS (Figure 1 - 3HDUVRQ¶V
correlation coefficient= -0.305). 
Who is assessed by LCNS 
Table 1 shows results for being assessed by a LCNS by patient features. The RRR of being assessed 
by a LCNS was 6% higher for men compared with women, but this association was accounted for 
when we adjusted for other patient features and Trust/LCNS features (RRR 1.02, 95% CI 0.96 -1.07). 
There was a clear association seen with age with patients >75 years less likely to be assessed. Patients 
with worse performance status (PS) and with comorbidities were also less likely to have been 
assessed. Patients with LC stage other than stage IA-IB and stage IV had a higher RRR of being 
assessed by a LCNS. The association with stage IV patients was not seen when we carried out a 
sensitivity analysis and restricted our analyses to patients who survived more than 30-days after 
diagnosis (Supplemental table 1).There was no difference by SES. We analysed missing data 
separately and that the RRR of missing data compared with patients not assessed revealed that there 
was no difference in being recorded as not seen between patients with stage IA-IB and stage IV. The 
amount of missing data was similar between patients from different SES (Supplemental table 2).  
Patients admitted through an emergency route were 57% less likely to have been assessed compared 
with those who were referred by a GP. Active treatment was also associated with assessment. Patients 
who had surgery were twice as likely to be assessed (RRR 2.04), while patients who receive 
chemotherapy alone or radiotherapy alone were three times as likely to be assessed (RRR 3.42 & 2.51 
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respectively). However, the strongest association was seen in patients who receive chemotherapy and 
radiotherapy, who were four times as likely to be assessed (RRR 3.93, 95% CI 3.10 ± 4.98). This 
association was also present in patients surviving more than 30-days post diagnosis. 
Patients first seen in a Trust with an annual LC caseload of >=265 patients were less likely to be 
assessed compared with smaller Trusts (adjusted RRR 0.58), but we found no association with 
increasing annual LCNS caseload. There was a higher likelihood of being assessed in Trust where the 
LCNS were on salary band 7 or 8 (RRR 1.59), however clustering by NHS Trusts widened the 
confidence interval and made the association non-significant. Patients first seen in Trusts where the 
majority of work was done by band 8 nurses were twice as likely to have been assessed compared 7 
band Trusts (RRR 2.22, 95%CI 1.22 ± 4.02), while trusts where majority of work is done by a band 6 
LCNS were less likely to have been assessed (RRR 0.71, 95% CI 0.47 ± 1.07). 
Point of lung cancer pathway where the patient is first assessed 
Table 2 shows results for the point at which the patient was first assessed by a LCNS (n=80,113). 
Patients with age >75 years, worsening PS and stage, other than stage IV, were less likely to be 
assessed before/at diagnosis but we found no difference with sex. Patients with a comorbidity score of 
higher than 4 were slightly more likely to be assessed before diagnosis than after diagnosis, while 
there was no difference with SES. Patients admitted through emergency were less likely to have been 
assessed before diagnosis; however those who were referred from another consultant were 76% more 
likely to have been assessed before receiving their lung cancer diagnosis. Patients having surgical 
treatment were almost twice more likely to have been assessed before/ at diagnosis than after 
diagnosis while significant association for patients receiving chemotherapy and radiotherapy was only 
present in patients surviving 30-days post LC diagnosis (Supplemental table 1). There was no 
association seen with the likelihood of being assessed before/ at diagnosis than after diagnosis with 
either increasing annual trust size or annual WTE LCNS caseload. LCNS on salary grade 7 or 8 were 
more likely to assess a patient before/at diagnosis than LCNS on a lower salary grade while there was 
no association seen with trusts were majority of work is done by either band 6, 7 or 8. 
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Where the patient is first assessed? 
Table 3 presents an overview of unadjusted and adjusted RRR of where the patients are first assessed 
by a LCNS. Over the years, the proportion of patients being assessed in clinics versus the proportion 
being assessed in wards has remained the same. Males and young people were 9% less likely to have 
been first assessed in a ward than in a clinic. The strongest association was seen with PS. Patients 
with PS 4 were almost 7 times more likely to have been first seen in a ward than in clinic. People with 
advanced stage and comorbidity were also associated with patients being more likely to have been 
first assessed in the ward. There was no difference in where the patient is first seen by SES, increasing 
annual WTE LCNS caseload or LCNS salary grade/majority work. Patients who receive any 
treatment are less likely to have their first assessment by a LCNS in wards than in clinic (RRR 0.48 
surgery, 0.47 chemotherapy and radiotherapy, 0.51 chemotherapy alone and 0.64 radiotherapy alone). 
Discussion 
Our results demonstrate an increase in the absolute proportion of patients assessed in recent years 
which is mainly driven by improvements in data completeness. However, the data reveals that older 
patients, with poorer PS, and those admitted through an emergency route are less likely to be assessed, 
which was still present in patients surviving more than 30-days after diagnosis, highlighting unmet 
need. However, it is possible that some patients are appropriately being referred to supportive and 
palliative care nurses, and that the LCNS is instrumental in making this happen. In contrast to 
research which indicates a more active approach to treatment in larger Trust, we found borderline 
moderate negative association between assessment and Trust size.  
Overall 32% of patients in our data had missing data. Even though the ascertainment of this 
information has improved in recent years, our results may be an underestimate of the true proportion 
of patients assessed by a LCNS.  
As reported previously, there is a strong association between assessment by a LCNS and active 
anticancer treatment [4]. We observed a higher likelihood of being assessed before diagnosis by a 
LCNS on a higher salary grade (i.e. 7 or 8) and a higher likelihood of being assessed where majority 
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of work is done by band 8 nurses. This may be linked to a better leadership qualities and an active 
involvement in MDT clinics by senior nurses. While patients diagnosed in a Trust with an annual 
Trust size of >265 were less likely to have been assessed, the effect of increasing caseload per WTE 
LCNS on the likelihood of being assessed was not present even when adjusted for several patient and 
Trust features. This may be due to differences in access to a LCNS, which were not examined in this 
study. 
This study uses a large representative dataset reflects real life LC care in England. Although the data 
entry in the NLCA is non-mandatory, the linked database has been validated [16]. The ascertainment 
of cases and data completeness has improved annually with recent audit result reports ascertainment 
closer to 100% [17]. We had a large proportion of patients with missing data on LCNS input; but the 
decreasing missing information in recent years associated with no change in the proportion of 
assessed vs not assessed in the database suggests that this was not deliberate (Supplemental table 2). 
This is the first time a snapshot of the LCNS workforce together with the patient level data was used 
to create an approximate patient caseload per WTE LCNS. Although we used the most recent data 
from the NCAT, the number of employed LCNS has remained relatively stable since 2007 (301 total 
LCNS in 2010 & 321 in 2011). Our results could be influenced by bias as patients with aggressive 
disease and short survival time may not have the opportunity to be assessed, however we conducted a 
sensitivity analysis limiting to all those patients who have survived for more than 30 days after 
diagnosis and observed the same association (Supplemental table 1). It could be argued for some 
patients opting for palliative treatment, a palliative care specialist nurse would be more effective at 
DWWHQGLQJ WR SDWLHQW¶V QHHGV, but we believe that the skills and expertise of the LCNS are 
complementary and should still be available.  
We created two variables to measure the effectiveness of LCNS based on their salary grade and the 
amount of work performed by them and observed a relationship of patients being assessed more and 
before diagnosis with Trusts where more senior nurses on higher salary bands are hired. With recent 
downgrading of nurses to band 6, our study highlights evidence of hiring more experienced nurses. It 
is very likely that many patients during the course of their treatment change nurses (for e.g. from 
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LCNS to specialist oncology nurse) and not all patients visit a LCNS each year survived after their 
diagnosis, however we believe that the number would be sufficiently small because of the poor 
survival rates [18] of LC and majority of the caseload for each LCNS comprised of new patients. 
Additionally, the surviving patients can still contact or can be referred to a LCNS from other CNSs. 
We assumed that being assessed in a clinic represented best practice as it signified patients contact 
with the LCNS during the initial LC pathways. This may not be the true for patients suffering from 
aggressive LC where they are first presented in emergency rather than visit to their GP. This would 
not make much difference as only 13% of the total LC population are referred to a lung physician in 
emergency, while around 50% are referred from GPs and other consultants [14 19 20]. 
The NICE guidelines have stated that every patient diagnosed with LC should have an access to a 
LCNS [1] while the NLCA audit suggesting that 80% of patients in each Trust should be assessed by 
a LCNS [12] and our results do provide evidence that most Trusts are now achieving this benchmark. 
In addition, there is also the presence of variation in caseload per WTE LCNS which is also observed 
in the NLCA annual audit reports [12 17]. 
We used a combination of database and survey to plot LCNS activities in NHS Trusts in England, and 
found that contact with LCNS was associated with increased likelihood of having received 
chemotherapy, radiotherapy and surgery. These results, except for surgery, are similar to results 
presented by Beckett and colleagues [4] who analysed patients in the NLCA in 2009. However, due to 
the retrospective analysis nature of the study and limited data on determining at which point in the LC 
pathway these patients were assessed, it is difficult to establish temporal relationship between being 
assessed and receiving anti-cancer therapy. Our results indicate that Trusts with low annual patient 
Trust size or with low per WTE LCNS caseload were more likely to assess patients which is similar to 
the Royal College of Physicians report [21], which found that multidisciplinary teams with low 
caseload per LCNS more likely to meet targets for outcomes. 
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Conclusion 
LCNS provide a valued service for patients suffering from LC however we found wide variations 
between patient features, annual Trust workload, LCNS caseload and who are assessed by a LCNS in 
between Trusts across England suggesting an unmet need of some patients with LC. To meet the 
needs of all people with LC and the clear targets set out by NICE, we need to expand the current 
LCNS workforce and ensure that we retain experienced nurses as LCNS are an integral part of the LC 
team and provide help to people with LC. 
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